J. Yang, H. Park, J. Byun, Sung Hwan Kim, Sung Ho Moon, Jong Duk Kim, Dea-Yeon Kim
{"title":"Risk Factors for poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis in south korea","authors":"J. Yang, H. Park, J. Byun, Sung Hwan Kim, Sung Ho Moon, Jong Duk Kim, Dea-Yeon Kim","doi":"10.7599/HMR.2016.36.4.262","DOIUrl":null,"url":null,"abstract":"Multi-drug resistant tuberculosis (MDR-TB) is a major health problem that threatens the success of tuberculosis (TB) control programs worldwide [1, 2]. The World Health Organization (WHO) launched the global surveillance project for anti-TB drug resistance in 1994 [1]. An estimated 3.3% (2.2-4.4%) of new cases and 20% (14-27%) of repeat TB cases were caused by MDR-TB in 2014, consistent with recent years [1]. In 2014, an estimated 480,000 people worldwide developed MDR-TB, and 190,000 people died as a result [1]. MDR-TB is caused by strains of Mycobacterium tuberculosis that are resistant to both isoniazid (INH) and rifampicin (RFP), the two most potent TB drugs. In 1965, the incidence of TB in South Korea was 668 cases per 100,000 [3]. Since the implementation of standardized therapeutic approaches in the 1980s, the prevalence of TB and Hanyang Med Rev 2016;36:262-268 https://doi.org/10.7599/hmr.2016.36.4.262 pISSN 1738-429X eISSN 2234-4446 Jun Ho Yang, M.D, Hyun Oh Park, M.D, Joung Hun Byun, M.D, Sung Hwan Kim, M.D, Sung Ho Moon, M.D, Jong Duk Kim, M.D and Dea Yeon Kim, M.D","PeriodicalId":345710,"journal":{"name":"Hanyang Medical Reviews","volume":"89 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hanyang Medical Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7599/HMR.2016.36.4.262","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Multi-drug resistant tuberculosis (MDR-TB) is a major health problem that threatens the success of tuberculosis (TB) control programs worldwide [1, 2]. The World Health Organization (WHO) launched the global surveillance project for anti-TB drug resistance in 1994 [1]. An estimated 3.3% (2.2-4.4%) of new cases and 20% (14-27%) of repeat TB cases were caused by MDR-TB in 2014, consistent with recent years [1]. In 2014, an estimated 480,000 people worldwide developed MDR-TB, and 190,000 people died as a result [1]. MDR-TB is caused by strains of Mycobacterium tuberculosis that are resistant to both isoniazid (INH) and rifampicin (RFP), the two most potent TB drugs. In 1965, the incidence of TB in South Korea was 668 cases per 100,000 [3]. Since the implementation of standardized therapeutic approaches in the 1980s, the prevalence of TB and Hanyang Med Rev 2016;36:262-268 https://doi.org/10.7599/hmr.2016.36.4.262 pISSN 1738-429X eISSN 2234-4446 Jun Ho Yang, M.D, Hyun Oh Park, M.D, Joung Hun Byun, M.D, Sung Hwan Kim, M.D, Sung Ho Moon, M.D, Jong Duk Kim, M.D and Dea Yeon Kim, M.D
耐多药结核病(MDR-TB)是威胁全球结核病(TB)控制规划成功的主要健康问题[1,2]。世界卫生组织(WHO)于1994年启动了全球抗结核耐药性监测项目[1]。2014年估计有3.3%(2.2-4.4%)的新发结核病例和20%(14-27%)的重复结核病例由耐多药结核引起，与近年来的情况一致[1]。2014年，全世界估计有48万人患上耐多药结核病，19万人因此死亡[1]。耐多药结核病是由对异烟肼(INH)和利福平(RFP)都具有耐药性的结核分枝杆菌菌株引起的，这是两种最有效的结核病药物。1965年，韩国结核病发病率为每10万人668例[3]。自20世纪80年代实施标准化治疗方法以来，结核病的患病率和汉阳医学Rev 2016;36:262-268 https://doi.org/10.7599/hmr.2016.36.4.262 pISSN 1738-429X eISSN 2234-4446 Jun Ho Yang, M.D, Hyun Oh Park, M.D, jung Hun byd, Sung Hwan Kim, M.D, Sung Ho Moon, M.D, Jong Duk Kim, M.D和Dea Yeon Kim, M.D
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
